Active substance
Warfarin
- SFDA 26
- US FDA 23
- Health Canada 16
- US price lines 18
- NHS prices 5
- WHO EML 1
- Safety 13
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| COUFATEX 1 mg Tablet | 1 mg | Tablet · Oral use | 100 Bottle | SAR 77.70 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| COUFATEX 2 mg Tablet | 2 mg | Tablet · Oral use | 100 Bottle | SAR 82.80 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| COUFATEX 5 mg Tablet | 5 mg | Tablet · Oral use | 100 Bottle | SAR 65.50 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| Coufatex | 2.5 mg | Tablet · Oral use | 100 Bottle | SAR 68.85 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| Coufatex | 3 mg | Tablet · Oral use | 100 Bottle | SAR 97.40 | Generic · Prescription | APOTEX | Valid |
| Coufatex | 4 mg | Tablet · Oral use | 100 Bottle | SAR 97.40 | Generic · Prescription | APOTEX | Valid |
| Coufatex | 10 mg | Tablet · Oral use | 100 Bottle | SAR 113.05 | Generic · Prescription | APOTEX | Valid |
| Solfarin | 1 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 815.00 | NCE · Prescription | Rosemont Pharmaceuticals Ltd | Valid |
| Warfarin Macleods | 5 mg | Tablet · Oral use | 100 Bottle | SAR 62.20 | Generic · Prescription | Macleods Pharmaceuticals Ltd. | Valid |
| Warfarin ZYD | 1 mg | Tablet · Oral use | 100 Bottle | SAR 73.80 | Generic · Prescription | Zydus Lifesciences Limited | Valid |
| Warfarin ZYD | 2 mg | Tablet · Oral use | 100 Bottle | SAR 78.65 | Generic · Prescription | Zydus Lifesciences Limited | Valid |
| Warfarin ZYD | 2.5 mg | Tablet · Oral use | 100 Bottle | SAR 65.40 | Generic · Prescription | Zydus Lifesciences Limited | Valid |
| Warfarin ZYD | 3 mg | Tablet · Oral use | 100 Bottle | SAR 92.55 | Generic · Prescription | Zydus Lifesciences Limited | Valid |
| Warfarin ZYD | 5 mg | Tablet · Oral use | 100 Bottle | SAR 62.20 | Generic · Prescription | Zydus Lifesciences Limited | Valid |
| Warfarin ZYD | 10 mg | Tablet · Oral use | 100 Bottle | SAR 107.40 | Generic · Prescription | Zydus Lifesciences Limited | Valid |
| COUMADIN | 7.5 mg | Tablet · Oral use | 100 Blister | SAR 131.80 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| COUMADIN | 2.5 mg | Tablet · Oral use | 100 Blister | SAR 142.30 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| COUMADIN | 2.5 mg | Tablet · Oral use | 100 Blister | SAR 105.65 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| COUMADIN | 2 mg | Tablet · Oral use | 100 Blister | SAR 99.60 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| COUMADIN | 5 mg | Tablet · Oral use | 100 Blister | SAR 114.75 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| COUMADIN | 5 mg | Tablet · Oral use | 100 Blister | SAR 99.60 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| COUMADIN | 2 mg | Tablet · Oral use | 100 Blister | SAR 109.55 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| COUMADIN | 10 mg | Tablet · Oral use | 100 Blister | SAR 118.60 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| WARFARIN SODIUM 1MG TAB | 1 mg | Tablet · Oral use | 28 Blister | SAR 11.40 | Generic · Prescription | IVAX PHARMACEUTICALS | Withdrawn by MAH · Not Marketed |
| WARFARIN SODIUM 3MG TAB | 3 mg | Tablet · Oral use | 28 Blister | SAR 15.75 | Generic · Prescription | IVAX PHARMACEUTICALS | Withdrawn by MAH · Not Marketed |
1 more — full table
Indications — CHI Daman Drug Formulary
ANTIPHOSPHOLIPID SYNDROME; ATRIAL FIBRILLATION; CARDIOMYOPATHY; CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); FOLLICULAR LYMPHOMA; HIP AND KNEE REPLACEMENT SURGERY; HODGKIN'S LYMPHOMA; ISCHEMIC STROKE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYELOFIBROSIS-ADVERSE REACTION MANAGEMENT; POLYCYTHEMIA VERA - THROMBOSIS; PORTAL VEIN THROMBOSIS; PULMONARY ARTERIAL HYPERTENSION; PULMONARY EMBOLISM; T-CELL LYMPHOMA-RENAL TOXICITY; VENOUS THROMBOEMBOLISM DISEASE (VTE)-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| WARFARIN SODIUM | 10MG; 1MG; 2MG; 2.5MG; 3MG; 4MG; 5MG; 6MG; 7.5MG | tablet · oral | TARO | Prescription | 15 Jul 1999 |
| JANTOVEN | 1MG; 2MG; 2.5MG; 3MG; 4MG; 5MG; 6MG; 7.5MG; 10MG | tablet · oral | UPSHER SMITH LABS | Prescription | 2 Oct 2003 |
| WARFARIN SODIUM | 1MG; 2MG; 2.5MG; 3MG; 4MG; 5MG; 6MG; 7.5MG; 10MG | tablet · oral | ZYDUS PHARMS USA | Prescription | 30 May 2006 |
| WARFARIN SODIUM | 2MG; 2.5MG; 3MG; 4MG; 5MG; 6MG; 7.5MG; 10MG; 1MG | tablet · oral | PLIVA | Prescription | 5 Jul 2006 |
| WARFARIN SODIUM | 1MG; 2MG; 2.5MG; 3MG; 4MG; 5MG; 6MG; 7.5MG; 10MG | tablet · oral | INVAGEN PHARMS | Prescription | 25 May 2011 |
| WARFARIN SODIUM | 1MG; 2MG; 2.5MG; 3MG; 4MG; 5MG; 6MG; 7.5MG; 10MG | tablet · oral | AMNEAL PHARMS | Prescription | 4 Mar 2013 |
| COUMADIN | 10MG; 5MG; 2MG; 7.5MG; 2.5MG; 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 4MG; 3MG; 6MG | tablet · oral | BRISTOL MYERS SQUIBB | Discontinued | 8 Jun 1954 |
| COUMADIN | 75MG/VIAL; 50MG/VIAL; 5MG/VIAL | injectable · injection | BRISTOL MYERS SQUIBB | Discontinued | 8 Jun 1954 |
| PANWARFIN | 2MG; 2.5MG; 5MG; 7.5MG; 10MG | tablet · oral | ABBOTT | Discontinued | 11 Aug 1972 |
| WARFARIN SODIUM | 1MG; 2MG; 2.5MG; 4MG; 5MG; 7.5MG; 10MG; 3MG; 6MG | tablet · oral | BARR | Discontinued | 26 Mar 1997 |
| WARFARIN SODIUM | 1MG; 2MG; 2.5MG; 4MG; 5MG; 7.5MG; 10MG; 3MG; 6MG | tablet · oral | CHARTWELL RX | Discontinued | 30 Sep 1997 |
| WARFARIN SODIUM | 1MG; 2MG; 2.5MG; 3MG; 4MG; 5MG; 6MG; 7.5MG; 10MG | tablet · oral | AUROBINDO PHARMA USA | Discontinued | 27 Sep 2004 |
| WARFARIN SODIUM | 1MG; 2MG; 2.5MG; 3MG; 4MG; 5MG; 6MG; 7.5MG; 10MG | tablet · oral | AIPING PHARM INC | Discontinued | 27 Jun 2013 |
| WARFARIN SODIUM | 7.5MG | tablet · oral | WATSON LABS | Discontinued | |
| WARFARIN SODIUM | 5MG | tablet · oral | WATSON LABS | Discontinued | |
| WARFARIN SODIUM | 2.5MG | tablet · oral | WATSON LABS | Discontinued | |
| WARFARIN SODIUM | 10MG | tablet · oral | WATSON LABS | Discontinued | |
| WARFARIN SODIUM | 2MG | tablet · oral | WATSON LABS | Discontinued | |
| WARFARIN SODIUM | 2MG | tablet · oral | USL PHARMA | Discontinued | |
| WARFARIN SODIUM | 2.5MG | tablet · oral | USL PHARMA | Discontinued | |
| WARFARIN SODIUM | 5MG | tablet · oral | USL PHARMA | Discontinued | |
| ATHROMBIN | 25MG; 10MG; 5MG | tablet · oral | PHARM RES ASSOC | Discontinued | |
| ATHROMBIN-K | 5MG; 10MG; 25MG; 2MG | tablet · oral | PHARM RES ASSOC | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-WARFARIN | 02242924 | 1 MG | TABLET · ORAL | APOTEX INC |
| APO-WARFARIN | 02242925 | 2 MG | TABLET · ORAL | APOTEX INC |
| APO-WARFARIN | 02242926 | 2.5 MG | TABLET · ORAL | APOTEX INC |
| APO-WARFARIN | 02242927 | 4 MG | TABLET · ORAL | APOTEX INC |
| APO-WARFARIN | 02242928 | 5 MG | TABLET · ORAL | APOTEX INC |
| APO-WARFARIN | 02242929 | 10 MG | TABLET · ORAL | APOTEX INC |
| APO-WARFARIN | 02245618 | 3 MG | TABLET · ORAL | APOTEX INC |
| TARO-WARFARIN | 02242680 | 1 MG | TABLET · ORAL | TARO PHARMACEUTICALS INC |
| TARO-WARFARIN | 02242681 | 2 MG | TABLET · ORAL | TARO PHARMACEUTICALS INC |
| TARO-WARFARIN | 02242682 | 2.5 MG | TABLET · ORAL | TARO PHARMACEUTICALS INC |
| TARO-WARFARIN | 02242683 | 3 MG | TABLET · ORAL | TARO PHARMACEUTICALS INC |
| TARO-WARFARIN | 02242684 | 4 MG | TABLET · ORAL | TARO PHARMACEUTICALS INC |
| TARO-WARFARIN | 02242685 | 5 MG | TABLET · ORAL | TARO PHARMACEUTICALS INC |
| TARO-WARFARIN | 02242686 | 6 MG | TABLET · ORAL | TARO PHARMACEUTICALS INC |
| TARO-WARFARIN | 02242687 | 10 MG | TABLET · ORAL | TARO PHARMACEUTICALS INC |
| TARO-WARFARIN | 02242697 | 7.5 MG | TABLET · ORAL | TARO PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | JANTOVEN 1 MG TABLET | $0.09856 | per EA | 23 Sep 2026 |
| US NADAC | JANTOVEN 10 MG TABLET | $0.10627 | per EA | 23 Sep 2026 |
| US NADAC | JANTOVEN 2 MG TABLET | $0.09296 | per EA | 23 Sep 2026 |
| US NADAC | JANTOVEN 2.5 MG TABLET | $0.09608 | per EA | 23 Sep 2026 |
| US NADAC | JANTOVEN 3 MG TABLET | $0.09864 | per EA | 23 Sep 2026 |
| US NADAC | JANTOVEN 4 MG TABLET | $0.09565 | per EA | 23 Sep 2026 |
| US NADAC | JANTOVEN 5 MG TABLET | $0.08882 | per EA | 23 Sep 2026 |
| US NADAC | JANTOVEN 6 MG TABLET | $0.09814 | per EA | 23 Sep 2026 |
| US NADAC | JANTOVEN 7.5 MG TABLET | $0.08912 | per EA | 23 Sep 2026 |
| US NADAC | WARFARIN SODIUM 1 MG TABLET | $0.09856 | per EA | 23 Sep 2026 |
| US NADAC | WARFARIN SODIUM 10 MG TABLET | $0.10627 | per EA | 23 Sep 2026 |
| US NADAC | WARFARIN SODIUM 2 MG TABLET | $0.09296 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Warfarin 1mg tablets | £1.06 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Warfarin 1mg/ml oral suspension sugar free | £209.72 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Warfarin 3mg tablets | £0.86 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Warfarin 500microgram tablets | £1.43 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Warfarin 5mg tablets | £0.86 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 10.2. Medicines affecting coagulation · core (EML); complementary (EMLc)
Venous thromboembolism; Cerebral ischaemic stroke due to embolic occlusion; Atrial fibrillation; Other specified diseases of arteries or arterioles
Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium) (EMLc); 3 mg (scored) (sodium)
Safety signals and safety-related labeling changes
- MHRA 20 Jun 2024 Warfarin: be alert to the risk of drug interactions with tramadol
Taking warfarin and tramadol together can cause harmful drug interactions, which can raise the International Normalised Ratio (INR), and result in severe bruising and bleeding, which in some patients could be fatal. - EMA PRAC 30 Sep 2021 PRAC signal: Anticoagulant-related nephropathy
Action for MAH: update of the product information: Yes - EMA PRAC 6 May 2021 PRAC signal: Anticoagulant-related nephropathy
Action for MAH: update of the product information: No - EMA PRAC 14 Jan 2021 PRAC signal: Anticoagulant-related nephropathy
Action for MAH: update of the product information: No - US FDA 14 Aug 2017 COUMADIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 9 Jun 2017 PRAC signal: Serious adverse drug reactions (ADRs) including bleeding events following potential drug interaction between dasatinib and warfarin
Action for MAH: update of the product information: No - MHRA 18 Jul 2016 Warfarin: reports of calciphylaxis
Calciphylaxis is a very rare but serious condition causing vascular calcification and skin necrosis. - EMA PRAC 13 May 2016 PRAC signal: Calciphylaxis
Action for MAH: update of the product information: Yes - EMA PRAC 14 Jan 2016 PRAC signal: Calciphylaxis
Action for MAH: update of the product information: No - EMA PRAC 6 Nov 2015 PRAC signal: Bone density decreased
Action for MAH: update of the product information: No - EMA PRAC 9 Jul 2015 PRAC signal: Bone density decreased
Action for MAH: update of the product information: No - EMA PRAC 12 Mar 2015 PRAC signal: Bone density decreased
Action for MAH: update of the product information: No - MHRA 11 Dec 2014 Warfarin: product information to be amended to give clearer, up-to-date advice
We continue to receive a substantial number of serious and fatal adverse event reports for warfarin through our Yellow Card Scheme.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.